98%
921
2 minutes
20
Objectives: The issue of quality of medicine is a worldwide phenomenon and counterfeit, substandard, spurious, and adulterated (CSSA) drugs are a substantial threat to public health. This issue is rampant in the context of low-middle-income countries such as Pakistan. The current study involved a phenomenology-based qualitative approach to explore these drugs' perception, knowledge, practice, and issues in combating this menace.
Methods: A semi-structured interview guide was developed. Eleven drug law experts were interviewed through a purposive sampling technique. All interviews were audio recorded, transcribed verbatim, and analysed using a framework analysis approach, yielding seven distinct themes.
Results: The results showed that CSSA drugs are a serious public health threat and drug law experts confirmed its prevalence in the market. They indicated shortcomings in legislation up to the extent of undue amendments, failure to interpret and implement the law by regulators, ineffective law enforcement machinery, the sub-optimum performance of quality control boards, drug testing laboratories, and courts, and the dubious role of rogue middlemen and wholesalers in drug supply chain and corruption were salient issues highlighted.
Conclusion: The study revealed that proper drug surveillance, ensuring the presence of a pharmacist, enforcing the law, securing the supply chain, infrastructure for a drug control regime, and training regulators can help tackle this problem.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12021191 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0322188 | PLOS |
J Pharm Policy Pract
September 2025
School of Public Health, Peking University, Beijing, People's Republic of China.
Background: The Market Authorization Holder (MAH) system in China, which separates marketing authorisation from production authorisation, was piloted in 2016 across 10 provinces and cities and was fully implemented at the end of 2019 with the new revision of the 'Drug Administration Law of the People's Republic of China'. This study examines the impact of the MAH system on innovation in China's pharmaceutical industry.
Methods: Using data from A-share pharmaceutical enterprises between 2009 and 2023, this study employs a Propensity Score Matching Difference-in-Difference (PSM-DID) design.
Health Aff Sch
September 2025
National Pharmaceutical Council, Washington, DC 20006, United States.
Introduction: There is limited direct measurement of whether the Inflation Reduction Act (IRA) is beginning to influence investment strategy and decisions.
Methods: Using a standardized guide, we interviewed life science investors from a range of stages, investment sizes, and fund types to explore how incentives under the IRA have impacted investment decisions.
Results: We interviewed 31 active investors.
Wellcome Open Res
July 2025
Centers, for Antimicrobial Optimization Network, Infectious Diseases Institute, Makerere University, Kampala, 256, Uganda.
Antimicrobial resistance (AMR) remains a critical global health challenge, and is mainly due to inappropriate antimicrobial use in human and animal health sectors. This systematic review examines the roles of Community Animal Health Workers (CAHWs) and Community Health Workers (CHWs) in antimicrobial stewardship (AMS) across Africa where AMR burden is highest and AMS programs are limited. Following PRISMA guidelines, this systematic review analyzed 16 studies (2017-2024) from nine African nations.
View Article and Find Full Text PDFUnlabelled: Policy Points Among patients with chronic noncancer pain, state medical cannabis laws did not impact health care use for opioid use disorder. There were no changes in health care use for opioid overdose attributable to medical cannabis laws. Medical cannabis laws do not appear to lead to reductions in adverse opioid-related outcomes.
View Article and Find Full Text PDFCancer Immunol Immunother
September 2025
Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, CHUV/UNIL, 1011, Lausanne, Switzerland.
Background: Immunotherapy is a mainstay in the treatment of patients with advanced melanoma. Yet, resistance mechanisms exist, and tumour-associated macrophages (TAMs), particularly the M2-like phenotype, are associated with poorer outcomes, with CD206 serving as their specific marker. We present the first human SPECT/CT study to visualize CD206 + TAMs in patients undergoing immunotherapy and compare the findings to clinical outcomes (NCT04663126).
View Article and Find Full Text PDF